Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Regulating HS1 function in response to ibrutinib therapy in CLL

Here, Cristina Scielzo, PhD, IRCCS, San Raffaele Scientific Institute, Milan, Italy, discusses the how 3D-culture of tumor cells within a bioreactor has helped identify the bone marrow as a key regulator of HS1 function when exposed to ibrutinib therapy. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.